[MAYBANK] QoQ TTM Result on 31-Mar-2013 [#1]

Announcement Date
23-May-2013
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2013
Quarter
31-Mar-2013 [#1]
Profit Trend
QoQ- 2.77%
YoY- 16.06%
View:
Show?
TTM Result
31/12/13 30/09/13 30/06/13 31/03/13 31/12/12 30/09/12 30/06/12 CAGR
Revenue 33,250,767 32,784,185 32,514,039 31,850,579 31,606,691 30,541,527 28,609,780 10.51%
PBT 8,869,594 8,517,746 8,190,838 8,128,456 7,896,302 7,677,158 7,492,132 11.87%
Tax -2,098,261 -2,004,863 -1,936,720 -2,017,147 -1,977,618 -1,980,426 -1,964,262 4.48%
NP 6,771,333 6,512,883 6,254,118 6,111,309 5,918,684 5,696,732 5,527,870 14.44%
-
NP to SH 6,552,391 6,280,182 6,035,081 5,905,253 5,745,920 5,545,034 5,371,839 14.11%
-
Tax Rate 23.66% 23.54% 23.64% 24.82% 25.04% 25.80% 26.22% -
Total Cost 26,479,434 26,271,302 26,259,921 25,739,270 25,688,007 24,844,795 23,081,910 9.55%
-
Net Worth 45,915,689 44,545,246 44,051,346 43,343,055 42,237,634 37,136,383 35,924,617 17.72%
Dividend
31/12/13 30/09/13 30/06/13 31/03/13 31/12/12 30/09/12 30/06/12 CAGR
Div 4,677,287 4,720,732 4,720,732 5,253,669 5,253,669 5,178,707 5,178,707 -6.54%
Div Payout % 71.38% 75.17% 78.22% 88.97% 91.43% 93.39% 96.40% -
Equity
31/12/13 30/09/13 30/06/13 31/03/13 31/12/12 30/09/12 30/06/12 CAGR
Net Worth 45,915,689 44,545,246 44,051,346 43,343,055 42,237,634 37,136,383 35,924,617 17.72%
NOSH 8,846,271 8,709,940 8,599,747 8,428,729 8,441,786 7,852,903 7,712,124 9.55%
Ratio Analysis
31/12/13 30/09/13 30/06/13 31/03/13 31/12/12 30/09/12 30/06/12 CAGR
NP Margin 20.36% 19.87% 19.24% 19.19% 18.73% 18.65% 19.32% -
ROE 14.27% 14.10% 13.70% 13.62% 13.60% 14.93% 14.95% -
Per Share
31/12/13 30/09/13 30/06/13 31/03/13 31/12/12 30/09/12 30/06/12 CAGR
RPS 375.87 376.40 378.08 377.88 374.41 388.92 370.97 0.87%
EPS 74.07 72.10 70.18 70.06 68.07 70.61 69.65 4.17%
DPS 52.87 54.20 54.89 62.33 62.23 65.95 67.15 -14.69%
NAPS 5.1904 5.1143 5.1224 5.1423 5.0034 4.729 4.6582 7.45%
Adjusted Per Share Value based on latest NOSH - 8,428,729
31/12/13 30/09/13 30/06/13 31/03/13 31/12/12 30/09/12 30/06/12 CAGR
RPS 275.55 271.69 269.45 263.95 261.93 253.10 237.09 10.51%
EPS 54.30 52.04 50.01 48.94 47.62 45.95 44.52 14.11%
DPS 38.76 39.12 39.12 43.54 43.54 42.92 42.92 -6.55%
NAPS 3.8051 3.6915 3.6506 3.5919 3.5003 3.0775 2.9771 17.72%
Price Multiplier on Financial Quarter End Date
31/12/13 30/09/13 30/06/13 31/03/13 31/12/12 30/09/12 30/06/12 CAGR
Date 31/12/13 30/09/13 28/06/13 29/03/13 31/12/12 28/09/12 29/06/12 -
Price 9.94 9.84 10.40 9.35 9.20 9.01 8.70 -
P/RPS 2.64 2.61 2.75 2.47 2.46 2.32 2.35 8.04%
P/EPS 13.42 13.65 14.82 13.35 13.52 12.76 12.49 4.89%
EY 7.45 7.33 6.75 7.49 7.40 7.84 8.01 -4.70%
DY 5.32 5.51 5.28 6.67 6.76 7.32 7.72 -21.92%
P/NAPS 1.92 1.92 2.03 1.82 1.84 1.91 1.87 1.76%
Price Multiplier on Announcement Date
31/12/13 30/09/13 30/06/13 31/03/13 31/12/12 30/09/12 30/06/12 CAGR
Date 27/02/14 21/11/13 21/08/13 23/05/13 21/02/13 09/11/12 16/08/12 -
Price 9.70 9.55 10.00 10.08 8.93 9.02 8.94 -
P/RPS 2.58 2.54 2.64 2.67 2.39 2.32 2.41 4.63%
P/EPS 13.10 13.24 14.25 14.39 13.12 12.77 12.83 1.39%
EY 7.64 7.55 7.02 6.95 7.62 7.83 7.79 -1.28%
DY 5.45 5.68 5.49 6.18 6.97 7.31 7.51 -19.19%
P/NAPS 1.87 1.87 1.95 1.96 1.78 1.91 1.92 -1.73%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ & YoY figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment